Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IONIS-AGT-LRx in Healthy Volunteers
NCT03101878Phase 1Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Apr 2017
- Primary completion
- Mar 2018
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hypertension (HTN) comparing Ionis AGT-LRx with Placebo (2 arms). Primary endpoints: Incidence and severity of adverse events up to 127 days, Changes in Blood Pressure measurements up to 127 days and 2 more. Started Apr 2017; status: completed.
02
Drugs
evazarsen
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT03101878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03101878.